Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Private Placement Update

Newsfile December 29, 2020

Hemostemix Announces Corporate Update

Newsfile December 23, 2020

Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement

Newsfile December 18, 2020

InvestmentPitch Media Video Discusses Hemostemix Successfully Obtaining all Clinical Trial Data and Announcement of $2.5 Million Unit Offering - Video Available on Investmentpitch.com

Newsfile December 1, 2020

Hemostemix Announces Possession of All Clinical Trial Data and $2,500,000 Unit Financing

Canadian Press, with file by Stockhouse November 27, 2020

Hemostemix Announces Closing Of Private Placement

Canadian Press, with file by Stockhouse November 25, 2020

The story of how a biotech co. came to the aid of an ill 9-year-old boy

Featured Submission October 14, 2020

Hemostemix Announces Partial Win in Florida

Canadian Press, with file by Stockhouse October 8, 2020

Treatment for Vascular Diseases: Blood-Based Stem Cells are Preferred Medically and Scale Commercially

Stockhouse Editorial October 1, 2020

Hemostemix Announces Private Placement and Debt Settlement

Canadian Press, with file by Stockhouse September 29, 2020

Hemostemix Announces Dr. Pierre Leimgruber As Interim Chief Medical Officer

Canadian Press, with file by Stockhouse September 23, 2020

Hemostemix provides litigation update

Canadian Press, with file by Stockhouse September 22, 2020

Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020

Newsfile July 13, 2020

Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019

Newsfile July 10, 2020

Hemostemix Announces Closing of Private Placement

Newsfile July 9, 2020

Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix's Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Science

Newsfile July 6, 2020

Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data

Newsfile July 3, 2020

Hemostemix Appeals Alberta Court's Service Ex Juris Decision

Newsfile June 24, 2020

Stem Cell Innovators See Clinical Success in $250 Billion Ischemia Market

Stockhouse Editorial June 22, 2020

Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC

Newsfile June 19, 2020